Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse

Circulation Research

Volumn 107, Issue 7, 2010, Pages 888-897

  Thomas, Merlin C ^a   Pickering, Raelene J ^a   Tsorotes, Despina ^a   Koitka, Audrey ^a   Sheehy, Karen ^a   Bernardi, Stella ^b   Toffoli, Barbara ^c   Nguyen Huu, Thu Phuc ^a   Head, Geoffrey A ^a   Fu, Yi ^a   Chin Dusting, Jaye ^a   Cooper, Mark E ^a   Tikellis, Chris ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

angiotensin; angiotensin converting enzyme 2; atherosclerosis; inflammation

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN II [1-7]AMIDE[1 SARCOSINE]; APOLIPOPROTEIN E; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; ANGIOTENSIN DERIVATIVE; AUTACOID; DIPEPTIDYL CARBOXYPEPTIDASE; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA FLOW; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE; BONE MARROW CELL; CELL ADHESION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; GENOTYPE; LEUKOCYTE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULITIS; ANIMAL; AORTA DISEASE; BLOOD; C57BL MOUSE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSFORMED CELL LINE;

ANGIOTENSINS; ANIMALS; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; CELL LINE, TRANSFORMED; ENDOTHELIAL CELLS; INFLAMMATION MEDIATORS; LIPIDS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDYL-DIPEPTIDASE A; VASCULITIS;

EID: 77958001190     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.219279     Document Type: Article

References (36)

1. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104: 503-516.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
4. Lee MA, Bohm M, Paul M, Ganten D. Tissue renin-angiotensin systems. Their role in cardiovascular disease. Circulation. 1993;87(suppl IV):IV-7-IV-13.
5. Jacoby DS, Rader DJ. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med. 2003;163:1155-1164.
6. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605-1612.
7. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98:121-128.
8. Ekholm M, Kahan T, Jorneskog G, Broijersen A, Wallen NH. Angioten-sin II infusion in man is proinflammatory but has no short-term effects on thrombin generation in vivo. Thromb Res. 2009;124:110-115.
9. Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM, Dilley RJ, Cooper ME, Allen TJ. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apoli-poprotein E-deficient mice. Circulation. 2002;106:246-253.
10. Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME, Jandeleit-Dahm KA. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation. 2004;109:1536-1542.
11. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin- converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822-828.
12. Nakamura K, Koibuchi N, Nishimatsu H, Higashikuni Y, Hirata Y, Kugiyama K, Nagai R, Sata M. Candesartan ameliorates cardiac dysfunction observed in angiotensin-converting enzyme 2-deficient mice. Hypertens Res. 2008;31:1953-1961.
13. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
14. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87: e1-e9.
15. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238-33243.
16. Probstfield JL, O'Brien KD. Progression of cardiovascular damage: the role of renin-angiotensin system blockade. Am J Cardiol. 105:10A-20A.
17. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol. 2005;289:H2281-H2290.
18. Tikellis C, Bialkowski K, Pete J, Sheehy K, Su Q, Johnston C, Cooper ME, Thomas MC. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes. 2008;57:1018-1025.
19. Gurley SB, Allred A, Le TH, Griffiths R, Mao L, Philip N, Haystead TA, Donoghue M, Breitbart RE, Acton SL, Rockman HA, Coffman TM. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest. 2006;116:2218-2225.
20. Oudit GY, Kassiri Z, Patel MP, Chappell M, Butany J, Backx PH, Tsushima RG, Scholey JW, Khokha R, Penninger JM. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res. 2007;75:29-39.
21. Jackson K, Head GA, Morris BJ, Chin-Dusting J, Jones E, La Greca L, Mayorov DN. Reduced cardiovascular reactivity to stress but not feeding in renin enhancer knockout mice. Am J Hypertens. 2007;20:893-899.
22. Thomas MC, Tikellis C, Burns WM, Bialkowski K, Cao Z, Coughlan MT, Jandeleit-Dahm K, Cooper ME, Forbes JM. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol. 2005;16:2976-2984.
23. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-2138.
24. Knowles JW, Reddick RL, Jennette JC, Shesely EG, Smithies O, Maeda N. Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-) Apoe(-/-) mice are ameliorated by enalapril treatment. J Clin Invest. 2000;105:451-458.
25. Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2010;30:1606-1613.
26. Lovren F, Pan Y, Quan A, Teoh H, Wang G, Shukla PC, Levitt KS, Oudit GY, Al-Omran M, Stewart DJ, Slutsky AS, Peterson MD, Backx PH, Penninger JM, Verma S. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol. 2008;295:H1377-H1384.
27. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amucha-stegui CS, Ruiz P, Smithies O, Coffman TM. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest. 1999;104:1693-1701.
28. Gkaliagkousi E, Passacquale G, Douma S, Zamboulis C, Ferro A. Platelet activation in essential hypertension: implications for antiplatelet treatment. Am J Hypertens. 2010;23:229-236.
29. Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol. 2007;18: 1093-1102.
30. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449-2460. (Pubitemid 47529329)
31. Laxton RC, Hu Y, Duchene J, Zhang F, Zhang Z, Leung KY, Xiao Q, Scotland RS, Hodgkinson CP, Smith K, Willeit J, Lopez-Otin C, Simpson IA, Kiechl S, Ahluwalia A, Xu Q, Ye S. A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res. 2009;105:921-929.
32. Manning MW, Cassis LA, Daugherty A. Differential effects of doxy-cycline, a broad-spectrum matrix metalloproteinase inhibitor, on angio-tensin II-induced atherosclerosis and abdominal aortic aneurysms. Arte-rioscler Thromb Vasc Biol. 2003;23:483-488.
33. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87: e1-e9.
34. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838-14843.
35. Keidar S, Attias J, Coleman R, Wirth K, Scholkens B, Hayek T. Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin. J Cardiovasc Pharmacol. 2000;35:64-72.
36. Thomas MC, Tikellis C. Losing control: positive and negative feedback in the renin angiotensin system. Curr Hypertens Rev. 2009;5:222-226.